UPDATED Dec. 22, 12:35 p.m.
ICU Medical Inc. (NSDQ:ICUI) landed a patent victory over RyMed Technologies Inc.
An eight-person jury in the U.S. District Court for Delaware found that technology employed in Franklin, Tenn.-based RyMed’s InVision Plus IV connector infringes upon two patents owned by ICU Medical.
The patents cover technology found in ICU Medical’s CLAVE portfolio of needle free IV connectors, according to the company.
The Dec. 17 decision confirmed the validity of two of ICU Medical’s patents, according to the company.
The San Clemente-based medical device maker had 2009 sales of about $230 million and, in addition to its needle-less connectors, manufactures a family of medical products used to deliver intravenous fluids and cancer drugs.
The jury also determined that there was no willful patent infringement by RyMed and decided in the company’s favor for one of the three patents that ICU Medical sued over, according to RyMed.
“While we are disappointed in the jury’s decision on two of the three patents, the entire matter is not yet resolved. We believe that RyMed will be vindicated as these proceedings continue to move through the court system. In the meantime, we expect that the availability of our products will not be affected by this verdict,” RyMed CEO Dana Ryan said in prepared remarks.